OX40 immunotherapy shows responses in head and neck cancer, strongest in HPV-positive tumors
TL;DR Summary
Inhibrx’s experimental OX40-targeting immunotherapy produced tumor responses in head and neck cancers, with the most striking activity in HPV-positive tumors, though the benefit may be limited to that subset despite a long history of failed OX40 approaches.
- Inhibrx claims first win for long-sought immunotherapy target STAT
- Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability Fierce Biotech
- Inhibrx opens door to cancer vaccine combo for its OX40 agonist Endpoints News
- Inhibrx cancer therapy outperforms Merck’s Keytruda (INBX:NASDAQ) Seeking Alpha
- Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | Newswise newswise.com
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 2 min read
Condensed
90%
380 → 37 words
Want the full story? Read the original article
Read on STAT